Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT05239650

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) + mFOLFOX6 or HLX07 Monotherapy in Patients With Metastatic Colorectal Cancer

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Shanghai Henlius Biotech · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This is An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) + mFOLFOX6 or HLX07 Monotherapy in Patients with Metastatic Colorectal Cancer.

Conditions

Interventions

TypeNameDescription
DRUGHLX071000mg
DRUGHLX10200mg
DRUGmFOLFOX6OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2

Timeline

Start date
2022-07-15
Primary completion
2025-10-15
Completion
2026-10-15
First posted
2022-02-15
Last updated
2022-05-03

Source: ClinicalTrials.gov record NCT05239650. Inclusion in this directory is not an endorsement.